Use of Povetacicept in Treatment of IgA Nephropathy

EP: 1.Disease Progression of IgA Nephropathy

EP: 2.Foundational Therapies in IgA Nephropathy

EP: 3.Interrupting Disease Progression of IgA Nephropathy

EP: 4.New Therapies in IgA Nephropathy

EP: 5.Dual Inhibition of BlyS and APRIL in IgA Nephropathy

EP: 6.Clinical Trial Results From Emerging Therapies in IgA Nephropathy

Now Viewing

EP: 7.Use of Povetacicept in Treatment of IgA Nephropathy

EP: 8.The Future of IgA Nephropathy Treatment

This is a video synopsis/summary of a panel discussion involving Jonathan Barratt, PhD, FRCP, and Brad Rovin, MD.

Jonathan Barratt, PhD, FRCP, and Brad Rovin, MD, discuss the latest data on drugs targeting the B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) axis in IgA nephropathy (IgAN), presented at the American Society of Nephrology (ASN) meeting. The conversation highlights the growing interest and excitement in the nephrology community about these emerging therapies.

Dr Barratt mentions recent data on sibeprenlimab and povetacicept and emphasizes the significant attention these drugs received at the ASN meeting. He specifically discusses the promising results from sibeprenlimab, showcasing consistent and effective APRIL inhibition, resulting in a reduction in galactose-deficient IgA1 (Gd-IgA1) and translation to reduced proteinuria.

Dr Rovin provides insights into the presentation of data on povetacicept, emphasizing its impressive proteinuria reduction, even at what is referred to as a "low dose." Both experts acknowledge the need for further dose-ranging studies to determine optimal dosing.

The discussion extends to the potential applications of these drugs beyond IgAN. Dr Barratt highlights a patient with membranous nephropathy treated with povetacicept, showing a significant reduction in anti-PLA2R titers, suggesting a potential broader impact on autoantibody-mediated diseases.

The experts discuss the ability of these drugs to target different cell populations, providing a unique advantage in diseases where both pathogenic antibodies and autoantibodies play a role. Dr Barratt emphasizes the potential benefits in lupus, envisioning combined approaches with BAFF and APRIL inhibition.

Dr Rovin concludes by expressing excitement about the multifaceted applications of these drugs in various diseases and suggests rethinking the use of immunosuppression, aiming for effective treatment with reduced overt immunosuppression. The conversation underscores the transformative potential of BAFF and APRIL inhibitors in reshaping the landscape of nephrology therapeutics across multiple diseases.

Video synopsis is AI-generated and reviewed by HCPLive editorial staff.